PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 13, 2026Breast Cancer Research and Treatment0 citationsOpen Access

Defining prognostic subgroups and treatment outcomes in estrogen receptor low-positive de novo metastatic breast cancer

View Full Paper
MKMadelyn KlugmanMAMaya AboumradRCRuizhe Chen

Key Points

  • This research aims to identify prognostic subgroups and evaluate treatment outcomes for estrogen receptor low-positive metastatic breast cancer patients.
  • Analyze survival data based on PR-positivity among ER low-positive patients and ER-negative patients.
  • Evaluate the suitability of first-line endocrine therapy in ER low-positive patients.
  • PR-positivity correlates with improved survival for ER low-positive patients compared to ER-negative patients.
  • Endocrine therapy shows promise as a viable first-line treatment for ER low-positive metastatic cases.

Abstract

PR-positivity identifies a subgroup of ER low-positive dnMBC patients with superior survival compared to ER-negative patients. First-line treatment incorporating endocrine therapy may be appropriate to consider for ER low-positive patients.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Klugman et al. (2026) studied this question.

synapsesocial.com/papers/698ebf1d85a1ff6a93016434https://doi.org/10.1007/s10549-025-07872-7
Ask AI
Helpful
Bookmark
Share
View Full Paper